- Home
- PLCE vs GANX Comparison
PLCE vs GANX Comparison
Compare PLCE & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLCE | GANX |
|---|---|---|
| Founded | 1969 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.5M | 78.5M |
| IPO Year | 1997 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PLCE | GANX |
|---|---|---|
| Price | $2.41 | $1.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.50 | ★ $7.50 |
| AVG Volume (30 Days) | 307.0K | ★ 792.5K |
| Earning Date | 04-10-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.48 | ★ 31.46 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.41 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.53 | $1.41 |
| 52 Week High | $9.56 | $4.34 |
Technical Indicators
Market Signals| Indicator | PLCE | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 28.90 | 48.92 |
| Support Level | N/A | $1.66 |
| Resistance Level | $3.81 | $2.09 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 3.09 | 60.00 |
Price Performance
Historical ComparisonAbout PLCE Children's Place Inc. (The)
Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It designs, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names. The Company classifies its business into two segments: The Children's Place U.S. and The Children's Place International.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.